Press "Enter" to skip to content

The Red Cross signs a five-year deal with Cerus Corp, a provider of synthetic compound and UV illuminator used for proessing platelets; moves for a pricier blood treatment method, so hospitals call for more choices

Julie Appleby and Kaiser Health News at fortune.com report Americans generally don’t spend much time thinking about the nation’s blood supply.That’s mainly because the collection and distribution system is safe and efficient. But there’s a new behind-the-scenes challenge, according to some hospital officials, who fear a change in how blood platelets are handled will sharply…

This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.